Jazz Pharmaceuticals plc (JAZZ) Tuesday reported a decline in profit for the second quarter, due mainly to higher operating expenses, despite increased revenues.
The Dublin, Ireland-based company's second-quarter net profit was $27.15 million or $0.45 per share, compared to $33.20 million or $0.71 per share last year.
Adjusted income for the quarter rose to $66.17 million or $1.09 per share from $38.38 million or $0.82 per share in the prior-year quarter. On average, seven analysts polled by Thomson Reuters expected the company to earn $1.05 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenues for the quarter grew to $129.54 million from $64.57 million in the prior-year quarter. Six analysts had a consensus revenue estimate of $125.53 million for the quarter.
Looking ahead, the company expects full-year net income in the range of $139 million to $154 million or $2.34 to $2.57 per share and adjusted income to range between $282 million and $291 million or $4.70 and $4.85 per share. Revenues for the year are anticipated in the range of $605 million to $615 million. Analysts currently expect the company to earn $4.66 per share for the year, with revenues of $599.50 million.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.